Pioneers of Immuno-Oncology
Autor Neil Canavanen Limba Engleză Hardback – 30 oct 2017
Based entirely on interviews with the investigators, this book is the story of the IO pioneers. It's a story of failure, resurrection, and success. It's a story about science, it's a story about discovery, and intuition, and cunning. It's a peek into the lives and thoughts of some of the most gifted medical scientists on the planet.
This is not a textbook. This is a life book. This technology will save/is saving lives, and the book will celebrate the living, breathing, thinking, charming, arrogant, funny, obstinate, drinking-too-much, not-drinking-enough, amazing human beings who are making IO happen.
Preț: 160.41 lei
Nou
Puncte Express: 241
Preț estimativ în valută:
30.71€ • 31.92$ • 25.46£
30.71€ • 31.92$ • 25.46£
Carte disponibilă
Livrare economică 15-29 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781621822172
ISBN-10: 1621822176
Pagini: 250
Dimensiuni: 237 x 161 x 27 mm
Greutate: 0.68 kg
Editura: Cold Spring Harbor Laboratory Press
ISBN-10: 1621822176
Pagini: 250
Dimensiuni: 237 x 161 x 27 mm
Greutate: 0.68 kg
Editura: Cold Spring Harbor Laboratory Press
Notă biografică
Neil Canavan is a veteran journalist specializing in science and medicine, a career he embarked upon after earning a master's degree in molecular and cellular biodynamics from Rutgers University. With more than 15 years of reporting experience, and some 200 feature articles to his credit Neil has written for such news outlets as WebMD, Medscape, Drug Discovery and Development Magazine, and The Scientist. Currently, Neil is a contributing editor to The Oncology Business Review where he has written many articles on the technology of, and clinical outcomes for cancer immunotherapy. Since 2014 Neil has held the position of Scientific Advisor at The Trout Group, a New York-based investor relations firm focused on healthcare biotechnology. The Trout Group has 30 clients in the oncology space, with many of those companies pursuing the development of cancer immunotherapies.